Trial Profile
Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery And Postoperative Complications In Patients With Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Double-Blind, Randomized Controlled Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2022
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Neostigmine
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 13 Oct 2022 Status changed from recruiting to completed.
- 27 Oct 2021 Planned End Date changed from 30 Jun 2021 to 31 Jan 2022.
- 27 Oct 2021 Planned primary completion date changed from 30 May 2021 to 30 Dec 2021.